Convexia

Convexia operates through an end-to-end AI stack that accelerates drug sourcing and evaluation. It utilizes modular AI agents to analyze structured and unstructured data, enabling faster identification of high-potential drug candidates. Each asset undergoes expert review to ensure thorough evaluation before development.

Convexia is powered by over 50 custom-tuned AI models that assess various factors such as binding, toxicity, and pharmacokinetics. These models are designed to evaluate drug candidates across multiple domains, ensuring comprehensive analysis and risk assessment.

Convexia's main features include a modular AI architecture, a human-in-the-loop design for expert review, and advanced predictive modeling for success likelihood. It also offers tools for evaluating drug candidates based on market needs and competitive landscapes.

Convexia employs a combination of machine learning and semi-supervised learning techniques. This approach allows the platform to train on both labeled and unlabeled biomedical data, enhancing its ability to identify and evaluate drug assets effectively.